A Clinical Study of Multiple-dose Pharmacokinetics of Tolvaptan Tablets Administered Orally (15mg Daily) for Consecutively 7 Days in Chinese Patients With Hepatocirrhosis
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- Serum concentration of tolvaptan and its metabolites DM-4103 and DM-4107
研究概览
简要总结
For hepatic cirrhosis subjects with ascites or lower extremities, to study Pharmacokinetics, pharmacology, and safety of the drug under fasting condition.
详细描述
This study is to evaluate the multiple-dose pharmacokinetics, pharmacological actions and safety of Tolvaptan tablets administered orally (15 mg daily) for consecutively 7 days in Chinese adult patients with confirmed Child-Pugh Class B（score 7-9） hepatocirrhosis (accompanied by ascites).
Trial Design:
- Open, single-center, multi-dose pharmacokinetics study
- Study population:
Chinese adult patients with confirmed Child-Pugh Class B (score 7-9) hepatocirrhosis (accompanied by ascites) 3. Dosage and mode of administration of investigational product:
Oral administration of 1 tablet (15mg) once daily, for consecutive 7 days starting from day 1 of treatment. 4. Study duration:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hepatic Cirrhosis with ascites or lower extremities edema
- •Hospitalized patients
- •18 years old~75 years old
- •Inform Consent Form Signed
排除标准
- •Patients with any of the following diseases, complications or symptoms:
- •Hepatic encephalopathy (coma degree classification note 1 Grade 2 or above);
- •Malignant ascites;
- •Spontaneous bacterial peritonitis;
- •Likely to have gastrointestinal bleeding during the study period;
- •Heart failure (NYHA Note 2 Class Ⅲ andⅣ);
- •Anuria (daily urine output below 100mL);
- •Dysuria induced by urinary tract stenosis, calculus, or tumor.
- •Patients with any of the following history:
- •With gastrointestinal bleeding within 10 days prior to screening;
- •With cerebrovascular accident within 1 month prior to screening;
- •With gout attack within 1 month prior to screening;
- •With allergy or atopy to benzodiazepine drugs (benazepril hydrochloride, etc.).
- •Patients whose systolic blood pressure is below 90mmHg during screening;
- •Patients with abnormal values in the following lab examination indicators:
- •Serum creatinine higher than 2.5 times the upper limit of normal range, serum Na+>145mmol/L(or higher than the upper limit of normal range), serum K+> 5.5 mmol/L, uric acid>476µmol/L, child-Pugh score>10
- •Patients ineligible for oral medication
- •Patients in pregnancy or lactation; female of childbearing potential not taking contraceptive measures;
- •Patients having taken blood products including albumin products within 4 days prior to application of investigational product;
- •Patients having participated in clinical trials of other drugs within 1 month prior to screening;
- •Patients used to participate in clinical trials of Tolvaptan and take the said drug;
- •Patients determined by the investigator as illegible for the study.
研究组 & 干预措施
Tolvaptan 15mg tablet
干预措施: tolvaptan (Drug)
结局指标
主要结局
Serum concentration of tolvaptan and its metabolites DM-4103 and DM-4107
时间窗: blood sample will be collected at predose, 2,4,6,8,12,24 hour of first drug administration and predose of sixth drug administration and predose,2,4,6,8,12,24 hour of seventh drug administration
次要结局
- pharmacological parameter:Serum concentration of sodium and potassium(Blood sample will be collected at predose on day1;12,24hour of first dosing;before breakfast on day3 to day6;predose and 12,24hour of seventh dosing)
- pharmacological parameter:24-hr urine(From day-1 to day 8)